Literature DB >> 35125697

Analytical Method Validation for Estimation of Neurotransmitters (Biogenic Monoamines) from Cerebrospinal Fluid Using High Performance Liquid Chromatography.

Rohan V Lokhande1,2, Ganesh R Bhagure2, Alpa J Dherai1, Prasad R Naik1, Vrajesh P Udani3, Neelu A Desai3, Tester F Ashavaid1.   

Abstract

Biogenic amine neurotransmitters such as serotonin and dopamine are essential for signaling in both central and peripheral nervous system. Their metabolism is a multistep pathway and any defect in this results in alteration in metabolites of serotonin 5-Hydroxyindole acetic acid (5HIAA) and dopamine homovanillic acid (HVA) and 3-O-Methyl Dopa (3-OMD). Estimation of these metabolites in cerebrospinal fluid (CSF) assists in diagnosis of neurotransmitter defects. Their estimation is technically demanding and is currently available only in referral centers. We aimed to optimize a method for analysis of 5HIAA, HVA and 3-OMD. A high performance liquid chromatography (HPLC) method with electro chemical detector (ECD) was standardized for estimation. Analysis for method validation, reference range verification and clinical correlation was performed. Linearity obtained for 5-HIAA, HVA and 3-OMD was 65.35-2615.0 nmoles/l, 68.62-2745.0 nmoles/l and 236.5-4730.0 nmoles/l respectively. The coefficient of variation for internal quality controls ranged from 5 to 14% and the external proficiency testing samples (n = 16) were within peer group range. CSF metabolite levels of samples for reference range analysis overlapped with age matched ranges reported in literature. Among the 40 suspected patients analyzed for clinical testing four were found to have a neurotransmitter defect. These patients were then confirmed with molecular testing and clinical correlation. The method is validated and can be adapted in a clinical laboratory with analytical competence in HPLC. © Association of Clinical Biochemists of India 2021.

Entities:  

Keywords:  Abnormal neurotransmitter; Biogenic monoamine; Cerebrospinal fluid; HPLC; Validation

Year:  2021        PMID: 35125697      PMCID: PMC8799795          DOI: 10.1007/s12291-020-00949-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  12 in total

Review 1.  Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid.

Authors:  Keith Hyland
Journal:  Clin Chem       Date:  2008-02-29       Impact factor: 8.327

Review 2.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

3.  HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins.

Authors:  Aida Ormazabal; Angels García-Cazorla; Yolanda Fernández; Emilio Fernández-Alvarez; Jaume Campistol; Rafael Artuch
Journal:  J Neurosci Methods       Date:  2005-03-15       Impact factor: 2.390

4.  Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles.

Authors:  Alice Kuster; Jean-Baptiste Arnoux; Magalie Barth; Delphine Lamireau; Nada Houcinat; Cyril Goizet; Bérénice Doray; Stéphanie Gobin; Manuel Schiff; Aline Cano; Daniel Amsallem; Christine Barnerias; Boris Chaumette; Marion Plaze; Abdelhamid Slama; Christine Ioos; Isabelle Desguerre; Anne-Sophie Lebre; Pascale de Lonlay; Laurence Christa
Journal:  J Inherit Metab Dis       Date:  2017-09-18       Impact factor: 4.982

Review 5.  Clinical Use of CSF Neurotransmitters.

Authors:  Lance H Rodan; K Michael Gibson; Phillip L Pearl
Journal:  Pediatr Neurol       Date:  2015-06-11       Impact factor: 3.372

Review 6.  Monoamine neurotransmitters and movement disorders in children and adults.

Authors:  D Doummar; F Moussa; M-C Nougues; C Ravelli; M Louha; S Whalen; L Burglen; D Rodriguez; T Billette de Villemeur
Journal:  Rev Neurol (Paris)       Date:  2018-08-27       Impact factor: 2.607

7.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

8.  Prevalence of inherited neurotransmitter disorders in patients with movement disorders and epilepsy: a retrospective cohort study.

Authors:  Saadet Mercimek-Mahmutoglu; Sarah Sidky; Keith Hyland; Jaina Patel; Elizabeth J Donner; William Logan; Roberto Mendoza-Londono; Mahendranath Moharir; Julian Raiman; Andreas Schulze; Komudi Siriwardena; Grace Yoon; Lianna Kyriakopoulou
Journal:  Orphanet J Rare Dis       Date:  2015-02-08       Impact factor: 4.123

9.  The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders.

Authors:  Thomas Opladen; Elisenda Cortès-Saladelafont; Mario Mastrangelo; Gabriella Horvath; Roser Pons; Eduardo Lopez-Laso; Joaquín A Fernández-Ramos; Tomas Honzik; Toni Pearson; Jennifer Friedman; Sabine Scholl-Bürgi; Tessa Wassenberg; Sabine Jung-Klawitter; Oya Kuseyri; Kathrin Jeltsch; Manju A Kurian; Àngels Garcia-Cazorla
Journal:  Mol Genet Metab Rep       Date:  2016-10-20

10.  The Utility of CSF for the Diagnosis of Primary and Secondary Monoamine Neurotransmitter Deficiencies.

Authors:  A B Burlina; A Celato; G Polo; C Edini; A P Burlina
Journal:  EJIFCC       Date:  2017-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.